Cargando…

1129. Targeted Voriconazole Prophylaxis in Heart Transplantation Recipients

BACKGROUND: The use of antifungal prophylaxis, targeted or universal, remains controversial and unstudied. The goal of this study is to determine the role of targeted voriconazole prophylaxis (VORI) in prevention of invasive fungal infections (IFI) after heart transplantation (HT). METHODS: We condu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Michael, Echenique, Ignacio, Angarone, Michael, Anderson, Allen, Stosor, Valentina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255345/ http://dx.doi.org/10.1093/ofid/ofy210.962

Ejemplares similares

Real-World Experience of Voriconazole Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients: A Single-Center Study
por: Chan, Shuk-Ying, et al.
Publicado: (2017)

1129. Outpatient Prescribing During the COVID-19 Pandemic
por: Moorthy, Ganga, et al.
Publicado: (2021)

1291. Safety of Isavuconazole Compared with Voriconazole as Primary Antifungal Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients
por: Bogler, Yael, et al.
Publicado: (2020)

215a. Use of Viracor Cytomegalovirus T-Cell Immunity Panel (TCIP) to Predict the Risk of Recurrent Cytomegalovirus Infection in Solid Transplant Patients and Guide Appropriate Management
por: Vysniauskaite, Indre, et al.
Publicado: (2022)

1129. Assessment of Nurses’ Views on Antimicrobial Stewardship at a Pediatric Hospital
por: Yu, Diana, et al.
Publicado: (2019)

1129. Optimizing Feedback Strategies on the Infectious Diseases Inpatient Service
por: Clark, Eva, et al.
Publicado: (2020)

89. Efficacy and Tolerability of Voriconazole (VOR) vs. Isavuconazole (ISA) Prophylaxis (px) in Preventing Invasive Fungal Infections (IFI) in Lung Transplant Recipients (LTR)
por: Samanta, Palash, et al.
Publicado: (2019)

1109. Valgancyclovir Dosing for Cytomegalovirus Prophylaxis in Heart Transplant Recipients
por: Huang, Glen, et al.
Publicado: (2020)

1164. Epidemiology of Cryptococcal Infections in Non-HIV Patients: A 20-year Single Center Experience
por: Kumar, Rebecca Nirmal, et al.
Publicado: (2020)

2112. Voriconazole for Primary Prophylaxis: A Decade of Trends and Outcomes
por: Mourad, Ahmad, et al.
Publicado: (2019)

1733. Voriconazole Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplant: How Much Is Enough, Are Low Voriconazole Levels Associated With Opportunistic Infections, and What Are the Reasons for Discontinuation?
por: Hadjivassiliou, Giorgos, et al.
Publicado: (2019)

1129 Varicella in Belgium: a National One year Prospective Survey
por: Blumental, Sophie, et al.
Publicado: (2014)

Voriconazole-induced Myositis in a Double Lung Transplant Recipient
por: Soliman, Mohanad, et al.
Publicado: (2019)

Primary or Secondary Prophylaxis with Voriconazole Compared with Posaconazole for Prevention of Invasive Fungal Infections After Hematopoietic Stem Cell Transplantation
por: Jansen, Jeffrey W, et al.
Publicado: (2017)

PReS13-SPK-1129: Biologic therapies in SLE
por: Isenberg, DA
Publicado: (2013)

Voriconazole and target-site penetration into human tissue
por: Weiler, Stefan, et al.
Publicado: (2008)

1136. Universal Prophylaxis for Prevention of Invasive Aspergillus in Lung Transplant Recipients
por: Guenette, Alexis, et al.
Publicado: (2018)

1592. Safety of Oral Trimethoprim/Sulfamethoxazole Prophylaxis in Renal Transplant Recipients
por: Horvat, Courtney, et al.
Publicado: (2018)

2105. Liposomal Amphotericin B Use Before and After Implementation of Voriconazole Prophylaxis in Cancer Patients
por: Shams, Madeeha, et al.
Publicado: (2019)

2138. Impact of De-escalation of Antibiotic Surgical Prophylaxis in Lung Transplant Recipients
por: Gandotra, Sumit, et al.
Publicado: (2018)

2715. Toxicities and clinical consequences of valganciclovir prophylaxis in solid organ transplant recipients
por: Lahoud, Chloe, et al.
Publicado: (2023)

Fusarium Infection in a Kidney Transplant Recipient Successfully Treated with Voriconazole
por: Alkhunaizi, Ahmed M., et al.
Publicado: (2018)

Cost Analysis of the Use of Voriconazole, Posaconazole and Micafungin in the Primary Prophylaxis of Invasive Fungal Infections in Recipients of Allogeneic Hematopoietic Stem Cell Transplants
por: Grau, Santiago, et al.
Publicado: (2015)

Predictors of Adverse Events and Determinants of the Voriconazole Trough Concentration in Kidney Transplantation Recipients
por: Zhao, Yi‐Chang, et al.
Publicado: (2020)

The Effect of Voriconazole on Tacrolimus in Kidney Transplantation Recipients: A Real-World Study
por: Zhao, Yi-Chang, et al.
Publicado: (2022)

1086. Epidemiology, Risk Factors, and Effect of Antifungal Prophylaxis on Early Invasive Fungal Infection in Heart Transplant Recipients
por: Yetmar, Zachary A, et al.
Publicado: (2020)

82. Incidence rates of invasive aspergillosis among lung transplant recipients in timeperiods with universal and targeted antifungal prophylaxis - a nationwide cohort study
por: Crone, Cornelia G, et al.
Publicado: (2022)

804. Impact of Azithromycin Prophylaxis in Lung Transplant Recipients on the Risk of Nontuberculous Mycobacterial Infections
por: Workman, Adrienne, et al.
Publicado: (2018)

1664. The Impact of Levofloxacin Prophylaxis on Empiric Intravenous Antibiotic Use in Pediatric Hematopoietic Stem Cell Transplant Recipients
por: Prodanuk, Michael, et al.
Publicado: (2023)

755. Posaconazole versus voriconazole as antifungal prophylaxis for invasive fungal diseases in patients with hematological malignancies
por: Almutairy, Reem F, et al.
Publicado: (2020)

1571. Cost-Effectiveness Analysis of Duration of Valganciclovir Prophylaxis Among CMV Serology Mismatched (Donor+/Recipient−) Lung Transplant Recipients
por: Tomko, Heather, et al.
Publicado: (2018)

Voriconazole and the Risk of Keratinocyte Carcinomas Among Lung Transplant Recipients in the United States
por: D’Arcy, Monica E., et al.
Publicado: (2020)

1737. Impact of Therapeutic Drug Monitoring (TDM) of Azole Prophylaxis in Lung Transplant Recipients on the Development of Positive Fungal Events
por: Shah, Anooj, et al.
Publicado: (2019)

Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation
por: Marks, David I, et al.
Publicado: (2011)

Voriconazole as a secondary prophylaxis for cryptococcal meningitis during hematopoietic stem cell transplantation
por: Kashima, Emiko, et al.
Publicado: (2021)

1569. Incidence, Risk Factors, and Impact of Antiviral Prophylaxis Duration on Cytomegalovirus (CMV) Disease in High-Risk Donor Seropositive/Recipient Seronegative [D+R−] Orthotopic Heart Transplant Recipients (OHTR)
por: Carcoana, Allison Dumitriu, et al.
Publicado: (2018)

Epidemiological Investigation of Pediatric Fractures—A Retrospective Cohort Study of 1129 Patients
por: Xiao, Xiaoliang, et al.
Publicado: (2023)

635. Is Azole Prophylaxis in Liver Transplant Recipients Effective in Preventing Invasive Candidiasis in the Era of Emerging Resistance?
por: Gurram, Pooja R, et al.
Publicado: (2022)

636. Meningococcal Vaccination and Antibiotic Prophylaxis Practices in Solid Organ Transplant Recipients undergoing Eculizumab Therapy
por: Bhaimia, Eric, et al.
Publicado: (2022)

Recurrent and metastatic squamous cell carcinoma in lung transplant recipient on voriconazole: Lessons learned
por: Zhang, Shali, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_603gucbme1mfafk3nagqfivt40